SEG-2022-01 Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 376
- 试验地点
- 1
- 主要终点
- Age at Index Date
研究概览
简要总结
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Age at Index Date
时间窗: Day 1 of Year 2
Index date was defined as the date of the first crizanlizumab infusion
Gender at Index Date
时间窗: Day 1 of Year 2
Index date was defined as the date of the first crizanlizumab infusion
Race
时间窗: Day 1 of Year 2
Ethnicity
时间窗: Day 1 of Year 2
Insurance Type at Index Date
时间窗: Day 1 of Year 2
Index date was defined as the date of the first crizanlizumab infusion
Number of Patients Categorized by Comorbidity
时间窗: Baseline
Number of Patients who Received Long-acting Opioid Medication Before Starting Crizanlizumab
时间窗: Baseline
Number of Patients who Received Chronic Red Blood Cell Transfusion Therapy Before Starting Crizanlizumab Categorized by Duration of Therapy
时间窗: Baseline
Red blood cell transfusion therapy time intervals: * 0-3 months * 3-6 months * 6-12 months * \>12 months * Unknown
Number of Patients who Received Chronic Red Blood Cell Transfusion Therapy After Starting Crizanlizumab Categorized by Duration of Therapy
时间窗: Up to 1 year
Red blood cell transfusion therapy time intervals: * 0-3 months * 3-6 months * 6-12 months * \>12 months * Unknown
Number of Patients by Type of Disease Modifying Therapy (DMT) Received Pre- and Post-index Date
时间窗: Up to 2 years
Index date was defined as the date of the first crizanlizumab infusion. DMTs included: * Any SCD specific therapy * Hydroxyurea * Voxelotor * L-Glutamine * Other
次要结局
- Number of Doses Received by Patients Who Continued and Discontinued Crizanlizumab Treatment(1 year)
- Number of SCD-related Hospitalizations and Emergency Department Visits Pre- and Post-index Date(Up to 2 years)
- Length of Stay of SCD-related Hospitalization Visits Pre- and Post-index Date(Up to 2 years)